News & Updates

Show Multimedia Only

Steatotic liver disease common in people with metabolic, alcohol risk factors

Steatotic liver disease (SLD) appears to be highly prevalent among individuals with cardiometabolic or alcohol risk factors, while elevated liver stiffness and advanced liver fibrosis are not uncommon, reports a recent study.

Steatotic liver disease common in people with metabolic, alcohol risk factors

a day ago

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

07 Dec 2025

In patients with nonmetastatic hepatocellular carcinoma (HCC), treatment with upfront liver transplant or liver transplant with bridge systemic therapy results in significantly better improvements in overall survival (OS) compared with systemic therapy only, according to a study.

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

07 Dec 2025

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

04 Dec 2025

Patients who discontinue tenofovir alafenamide (TAF) therapy appear to have a higher hepatitis B virus relapse rate than those who ceased entecavir or tenofovir disoproxil fumarate (TDF) therapy, according to a recent study.

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

04 Dec 2025

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

Patients with cirrhosis using calcium channel blockers (CCBs) are not at increased risk of variceal haemorrhage, as reported in a retrospective study.

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

NAFLD/MAFLD carries increased risk of nephrolithiasis

22 Nov 2025

Patients with nonalcoholic fatty liver disease (NAFLD)/metabolic dysfunction–associated fatty liver disease (MAFLD) have an elevated risk of nephrolithiasis, according to a study.

NAFLD/MAFLD carries increased risk of nephrolithiasis

22 Nov 2025

Chronic HCV infection increases susceptibility to pancreatic cancer

19 Nov 2025

Chronic hepatitis C virus (HCV) infection contributes to an increased risk of pancreatic ductal adenocarcinoma (PDAC), as reported in a retrospective study.

Chronic HCV infection increases susceptibility to pancreatic cancer

19 Nov 2025

PFS a potential surrogate marker for OS in advanced BTC trials

13 Nov 2025

In advanced biliary tract cancer (BTC), progression-free survival (PFS) is moderately associated with overall survival (OS) both the trial- and patient-level analyses, while objective response rate (ORR) and disease control rate (DCR) show a low correlation.

PFS a potential surrogate marker for OS in advanced BTC trials

13 Nov 2025

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

13 Nov 2025 by

A 3-year update from the phase III TOPAZ-1 study has shown sustained survival benefit and manageable safety with durvalumab plus gemcitabine and cisplatin (GemCis) relative to placebo among patients with advanced biliary tract cancer (BTC).

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

13 Nov 2025

Rivaroxaban may prevent PHT-related complications in cirrhosis

13 Nov 2025

Treatment with rivaroxaban appears to improve portal hypertension (PHT)-related complications without increasing the risk of major bleeding in patients with cirrhosis and moderate liver dysfunction, a study has shown.

Rivaroxaban may prevent PHT-related complications in cirrhosis

13 Nov 2025

News & Updates

Showing Hepatology articles

Showing

Specialty:

Steatotic liver disease common in people with metabolic, alcohol risk factors

Steatotic liver disease common in people with metabolic, alcohol risk factors

Rifaximin does not improve survival in severe cirrhosis

Rifaximin does not improve survival in severe cirrhosis

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

Liver transplant tied to better survival than systemic therapy only in nonmetastatic HCC

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

Relapse higher in HBeAg- patients after cessation of TAF vs TDF, entecavir

CCBs not associated with variceal haemorrhage in cirrhosis

CCBs not associated with variceal haemorrhage in cirrhosis

NAFLD/MAFLD carries increased risk of nephrolithiasis

NAFLD/MAFLD carries increased risk of nephrolithiasis

Chronic HCV infection increases susceptibility to pancreatic cancer

Chronic HCV infection increases susceptibility to pancreatic cancer

PFS a potential surrogate marker for OS in advanced BTC trials

PFS a potential surrogate marker for OS in advanced BTC trials

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

Rivaroxaban may prevent PHT-related complications in cirrhosis

Rivaroxaban may prevent PHT-related complications in cirrhosis